Condyloma
Conditions
Keywords
condyloma, HIV
Brief summary
Caused by the human papillomavirus (HPV), anogenital warts are a common sexually-transmitted infection (STI). They are distressing to those who have them and are a source of viral shedding and transmission to others. Treatment of warts is aimed at destruction of the lesion. Objectives: 1. Establish safety of Multikine in treatment of perianal condyloma. 2. Describe presence of anal HPV and anal dysplasia in participants with perianal condyloma. 3. Describe adverse effects associated with Multikine in the management of perianal condyloma. Design: Phase I, dose-escalation trial. Potential participants desiring treatment for their perianal warts will be referred to study by their primary clinician. All participants will undergo baseline anal Pap, anal HPV subtyping, perianal condyloma characterization (count, measurement, photography), and complete a baseline questionnaire. Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days. If no serious adverse events are noted after 4 weeks of therapy, cohort B will be studied using the same schedule but with a dose of 400IU per treatment. Each participant will undergo anal Pap and anal HPV subtyping once weekly during treatment. Condyloma characterization (count, measurement, photography) will occur prior to each treatment. After treatment completed, participants will complete a follow-up visit at 70, 100, 130, 160 days and have anal Pap, anal HPV subtyping, and perianal condyloma characterization (count, measurement, photography) performed. Subjects: The study will be open to adult men and women who are HIV-infected who receive medical care from the Naval Medical Center San Diego. Main Outcome Measures: 1. Perianal wart characterization \[count, measurement (in millimeters diameter)\], photography) 2. HPV subtype in anal canal 3. Anal dysplasia cytologic grade 4. Questionnaire responses 5. Adverse effects experienced during treatment, recorded in symptom log
Detailed description
There are no further details to describe regarding this research project
Interventions
DRUGLeukocyte Interleukin, Injection 200IU
Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
DRUGLeukocyte Interleukin, injection 400IU
Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
Sponsors
CEL-SCI Corporation
United States Naval Medical Center, San Diego
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥18 years of age * Diagnosed with perianal condyloma by primary clinician * HIV-infected, may be on or off of antiretroviral therapy * any CD4 count will be considered appropriate for study * Blood WBC \> 2.0x103/mm3 and absolute neutrophils count \> 500 * Blood hemoglobin \> 10.0 g/dL * Blood platelet count \> 50x103/mm3 * Serum total bilirubin \< 6.0 mg/dL (participants taking atazanavir-based ARV regimens may have elevated total bilirubin but are generally \< 6) * Blood aspartate aminotransferase (AST) \< 100 U/L (\<2 ULN) * Blood alanine aminotransferase (ALT) \< 130 U/L (\<2 ULN) * Serum creatinine \< 1.5 mg/dL * ECOG performance status \< 3 * If a subject is of reproductive potential he/she and her/his sexual partner MUST be willing and able to utilize effective methods of contraception (e.g., birth control pill, barrier methods with spermicide - as applicable) for the duration of the study including the study follow-up period.
Exclusion criteria
* Anal cancer (current or history of) * Inability to attend study visits * Participation in any other drug study * History of asthma * History of organ transplantation or requiring chronic administration of immune suppressive drugs in the last 6 months * For women, neither pregnant nor lactating * In the opinion of the PI, the subject may not be able to tolerate the study treatment regimen
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Wart characterization change is being assessed | Days 0, 4, 11, 32, 39, 70, 100, 130, 160 | Perianal wart characterization includes counting the number of identified warts, the diameter measurement of each identified wart in millimeters and the photographic imaging of each identified wart during the treatment phase and the follow-up phase of the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HPV subtype identification change is being assessed | Days 0, 4, 11, 32, 39, 70, 100, 130, 160 | HPV subtype identification specimen collection from the anal canal will be conducted during the treatment phase and the follow-up phase of the study |
| Anal dysplasia cytologic grade change is being assessed | Days 0, 4, 11, 32, 39, 70, 100, 130, 160 | Anal dysplasia cytologic specimen collection will take place during the treatment phase and the follow-up phase of the study |
| Adverse effects during the treatment phase of the study are being assessed | Days 0, 4, 11, 32, 39, 70, 100, 130, 160 | Adverse effects experienced during the treatment phase of the study are recorded by the study participants in a symptoms log |
Countries
United States
Outcome results
None listed